Other Corporate Information – ASCELIA

All All press releases Regulatory press releases Financial reports

2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting

2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference

2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage

2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population

2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Regulatory

2022-03-07 | Ascelia Pharma suspends clinical activities in Russia

2022-03-02 | Issue and repurchase of series C shares for share saving program

2022-02-15 | Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR conference

2021-12-16 | Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial

2021-12-01 | Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Regulatory

2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB

2021-10-19 | Ascelia Pharma’s Food Effect Study with Orviglance successfully completed

Regulatory

2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF®

Regulatory

2021-08-18 | Covid-19 extends recruitment period of SPARKLE study

2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA

2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance

Regulatory

2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm